1.
Rindi G, Klöppel G, Ahlman H, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395–401.
2.
Rindi G, Klöppel G, Couvelard A, et al: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757–762.
3.
Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P: Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007;451(suppl 1):S9–S27.
4.
Plöckinger U, Wiedenmann B: Treatment of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007;451(suppl 1):S71–S80.
5.
Eriksson B, Kloppel G, et al: Consensus guidelines for the management of patients with digestive neuroendocrine tumors – well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008;87:8–19.
6.
Jensen RT, Rindi G, et al: Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology 2006;84:165–172.
7.
Nilsson O, Van Cutsem E, et al: Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006;84:212–215.
8.
O’Toole D, Salazar R, et al: Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006;84:189–195.
9.
Rindi G, de Herder WW, et al: Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about it. Neuroendocrinology 2006;84:155–157.
10.
Rindi G, de Herder WW, et al: Consensus guidelines for the management of patients with digestive neuroendocrine tumors: the second event and some final considerations. Neuroendocrinology 2008;87:5–7.
11.
Ruszniewski P, Delle Fave G, et al: Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 2006;84:158–164.
12.
Lloyd RV: Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol 2003;14:293–301.
13.
Bussolati G, Volante M, Papotti M: Classic and recent special stains used in differential diagnosis of endocrine tumors. Endocr Pathol 2001;12:379–387.
14.
Solcia E, Klöppel G, Sobin LH, in collaboration with 9 pathologists from 4 countries: Histological typing of endocrine tumours, ed 2. WHO International Histological Classification of Tumours. Berlin, Springer, 2000.
15.
Pelosi G, Bresaola E, Bogina G, et al: Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone recep tor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996;27:1124–1134.
16.
Reubi JC: Peptide receptor expression in GEP-NET. Virchows Arch 2007;451(suppl 1):S47–S50.
17.
Volante M, Righi L, Asioli S, Bussolati G, Papotti M: Goblet cell carcinoids and other mixed neuroendocrine/non-neuroendocrine neoplasms. Virchows Arch 2007;451(suppl 1):S61–S69.
18.
DeLellis RA, Lloyd RV, Heitz PU, Eng C: Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Tumours. Lyon, IARC Press, 2004.
19.
Rindi G, de Herder WW, O’Toole D, Wiedenmann B: Consensus guidelines for the management of patients with digestive neuroendocrine tumors: the second event and some final considerations. Neuroendocrinology 2008;87:5–7.
20.
Klöppel G: Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:15–31.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.